Clinical use of recombinant human hematopoietic growth factors.
Clinical use of recombinant human hematopoietic growth factors.
复制标题
重组人造血生长因子的临床应用。
DOI：
10.1093/jnci/81.18.1370
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
Moore,MA
中科院分区：
文献类型：
--
作者：
Laver,J;Moore,MA
造血生长因子是一类造血调节因子家族，具有支持不同血细胞增殖和分化的能力，具有生物学特性。这些因子的生物学特性是高度复杂的，依赖于剂量，并且经常重叠。最近在克隆造血细胞生长因子基因和重组材料的可用性方面的进展促使研究人员使用这些药物进行临床试验。其中一些因子已被研究并用于化疗引起的中性粒细胞增多、骨髓增生异常综合征和骨髓衰竭综合征。在这篇文章中，我们回顾了已经测试和目前正在临床试验中引入的生长因子的经验。此外，我们报告了一些临床医生和研究人员未来可能感兴趣的因素。[纳提癌症杂志81：1370-1382，]
Hematopoletic growth factors comprise a family of hematopoietic regulators with biologic specificities defined by their ability to support proliferation and differentiation of blood cells of different lineages. The biologic specificities of these factors are highly complex, dose dependent, and frequently overlapping. Recent advances In the cloning of hematopoietlc growth factor genes and the availability of recombinant material have led investigators to conduct clinical trials with these agents. Some of these factors have been studied and used In chemotherapy-induced neutropeala, myelodysplastic syndromes, and bone marrow failure syndromes. In this paper, we review the experience with growth factors that have been tested and that currently are being introduced in clinical trials. In addition, we report some factors with possible future interest for clinicians and researchers. [J Nati Cancer Inst 81:1370–1382, 1989]